Project Grant R01AI176494
Award Date
4/17/23
Completion Date
3/31/28
Dollars Obligated
$408K
Federal Agency
National Institute of Allergy and Infectious Diseases
Federal Grant Program
93.855
Assistance Type
Project Grant
Place of Performance
South Africa
Similar Awards
This federal Project Grant award of $233,528 from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) aims to delineate the transcriptomic responses in human peripheral blood and stool samples collected from volunteers after controlled infection with varying doses of two different strains of norovirus. The goal is to use these early innate transcriptional responses as predictors of the effective adaptive...
The federal Project Grant award R21AI185887 was provided by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855). The $516,900 grant awarded to Immport Therapeutics Inc. (doing business as Antigen Discovery Inc.) supports research to discover antibody correlates of protection against five common enteric viruses that cause diarrhea in infants, including adenovirus, astrovirus, norovirus, rotavirus, and...
The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $798,173 Project Grant under the Allergy and Infectious Diseases Research (CFDA 93.855) program to The Ohio State University. The 5-year grant, running from May 2025 to April 2030, will support the development of novel multivalent mucosal vaccines for human noroviruses (HuNoVs), a leading cause of acute gastroenteritis worldwide. The project aims to develop live-vectored mucosal HuNoV vaccines using the FDA-approved...
This Project Grant award of $721,728 from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) supports research to investigate the impact of persistent viral infections on sepsis outcomes and response to immunomodulatory therapies in pediatric patients. The key objectives are to: 1) Evaluate whether persistent infection with DNA viruses like cytomegalovirus and Epstein-Barr virus correlates with sepsis...
This federal Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $800,250 to the University of California, Santa Cruz (UCSC) to conduct research on the norovirus capsid protein. The goal is to define the epitopes recognized by neutralizing antibodies targeting the immunodominant antigenic site G on the norovirus capsid, and to visualize the chronological shift in antibody...
The University of Florida has been awarded a $659,313 Project Grant from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855). The grant aims to investigate how hypoxia (low oxygen levels) in the gastrointestinal tract impacts the antiviral immune response of human intestinal epithelial cells against enteric viruses such as rotavirus and norovirus. The research will leverage human intestinal organoids and...
This federal Project Grant award, funded by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), supports research to investigate the prevalence, clinical impact, and virus-host dynamics of SARS-CoV-2 and respiratory virus co-infections in children. With total funding of $2,353,903 over the award period from July 2024 to May 2029, the project aims to: 1) assess the prevalence of SARS-CoV-2 and respiratory...
This $188,980 Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID) under CFDA 93.855 (Allergy and Infectious Diseases Research) is funding research at The Washington University in Missouri to elucidate the role of intestinal M cells in rotavirus enteric infection, systemic dissemination, and pathogenesis. The key objectives are to determine the extraintestinal tissues and cell types targeted by rotavirus following oral inoculation, as well as to utilize a...
This Project Grant award for $1,376,850.00, provided by the National Institute of Child Health and Human Development (NICHD) under the Child Health and Human Development Extramural Research program (CFDA 93.865), aims to investigate interventions for protecting HIV-exposed uninfected (HEU) infants against severe infections. The key objectives are to: 1) define immunogenomic and metabolomic profiles that explain immune dysfunctions in HEU infants; 2) compare gut and respiratory microbiome...
This federal Project Grant award, valued at $668,488.00 and funded by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), supports research to investigate the mechanisms by which the rotavirus outer capsid protein VP4 interacts with the host cell's actin-related protein 2/3 (Arp2/3) complex to enable cell-to-cell transmission of the virus. The research aims to leverage expertise in rotavirus reverse genetics,...